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a b s t r a c t
Meningiomas (MGs) are the most frequent primary tumours of the central nervous system
(CNS) and exhibit a large spectrum of histological types and clinical phenotypes. The WHO
classiﬁcation of CNS tumours established strict diagnostic criteria of the benign (Grade 1),
atypical (Grade 2) and anaplastic (Grade 3) subtypes. Combined with the resection rate, WHO
grading has the most crucial role as the prognostic factor. Additionally, such biomarkers as
Ki-67/MIB-1, progesterone receptors and phosphor-histone H3 were correlated with MG
progression. Recently, it was suggested that the aggressive behaviour of some MGs is
attributed to molecular alterations, regardless of their histopathology. The analysis of loss
of heterozygosity (LOH) at chromosomes 1, 9, 10, 14 and 22 was performed. The presented
case of WHO Grade 2 MG initially exhibited LOH at chromosomes 10, 14 and 22. In the ﬁrst
recurrence, the tumour genetic proﬁling revealed additional LOH at chromosome 1p and
atypical histopathology. During the second recurrence, an aggressive phenotype was ob-
served and tumour progressed to an anaplastic form. Considering the appearance of the
tumour relapses, the set of molecular changes overtook the histopathological progression.
The genetic and histopathological imbalance in the tumour progression in secondary
anaplastic MGs has not been previously described. The evolution of genetic and histopatho-
logical changes was presented in the same patient. In the future, the individualised therapy
of potentially more aggressive forms of MGs could be based on certain chromosome
aberrations.
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Meningiomas (MGs) are the most common intracranial
tumours. They comprise 25–30% of the primary central
nervous system (CNS) neoplasms [1]. The origin of MGs is
unclear and arachnoid granulations with secondary invasion
of the dura mater is the most convincing hypothesis [2]. The
meningothelial hyperplasia of dural cells as a transitional
form of MG was regarded as a reason for multifocal occurrence
[3]. Histological diagnosis of a benign MG (Grade 1) is more
clear for the pathologist than diagnosis of atypical (Grade 2) or
anaplastic (Grade 3) types of this tumour. Microscopically, the
anaplastic form may under a microscope resemble a
carcinoma, sarcoma or melanoma, thus making an additional
immunohistochemistry necessary for establishing a ﬁnal
diagnosis [2]. According to the 2007 revision of the criteria for
CNS tumours [4], the World Health Organization (WHO)
classiﬁed some MGs to an 'invasive' subtype. Regarding
tumour recurrence, both the WHO grading and the resection
rate are the most powerful prognostic factors. Some authors
suggested other prognostic biomarkers, including Ki-67/MIB-
1, progesterone receptors and phosphor-histone H3 [5–7].
However, some MGs present with invasive behaviour,
regardless of their histopathology [2]. Their aggressive
behaviour may be attributed to the alterations at the
molecular level, similar to those described in other brain
neoplasms, e.g. glioblastomas. Accordingly, low- and high-
grade gliomas can be either of primary or of secondary origin.
A question arises whether this pattern be easily translated to
anaplastic MGs? De novo or secondary anaplastic origins of
MGs are at least debatable [4] and the molecular ﬁndings
illuminate the issue. Early reports suggested monosomy of 22/
22q as the most frequent aberration and the mutation
underlying the formation of MGs [8]. The alteration of severalFig. 1 – Imaging (a) and histopathological findings (H&E staining,
and second (3a-b) relapse. (a) Computer tomography (CT) imagin
oedema. (b). Atypical MG. Enlarged nuclei or prominent nucleoli
references to color in this figure legend, the reader is referred tochromosomes [1,6,9,10,14,18] is commonly found in Grade
2 but less often in Grade 1 MGs [8]. On the other hand, the
progression-associated loci were sparsely reported and
limited to losses of genetic material on 6q, 9p, 10q, 14q, or
ampliﬁcation of 17q23 [2,8]. We report an MG case in which the
evolution of genetic alterations explains the relapsing clinical
course. The molecular ﬁndings were unrelated to the
histopathology.
2. Case report
A 56-year-old male presented with persistent headache and
left hemiparesis. Medical history was signiﬁcant for diabetes
type 2 and hyperlipidaemia. Contrast-enhanced computed
tomography (CT) revealed a 5 cm meningioma in right frontal
convexity, with sagittal sinus invasion and apparent brain
oedema surrounding the lesion (Fig. 1a). Hemiparesis with-
drew within days after the operation and the whole postoper-
ative period was uneventful. Nevertheless the pathologist
diagnosed an atypical, grade 2 meningioma MG (Grade 2)
(Fig. 1b) and CT performed 6 months after the surgery revealed
a multifocal tumour relapse in the parasagittal area (Fig. 2a).
The tumour was removed together with its multidirectional
extensions during the second-look surgery (Simpson grade 2)
and again HP conﬁrmed atypical features of recurrent MG
(Fig. 2b). After 4 months the neoplasm relapsed again, this time
as a tumour disseminated from its primary location along the
falx (Fig. 3a). Third surgery was undertaken to result in
Simpson grade 2 resection of all numerous round-shaped
tumour extensions. HP examination revealed anaplastic
transformation (Fig. 3b), therefore adjuvant radiotherapy
was applied (unknown total dose). The anaplastic MG recurred
again two times: two rescue partial resections were performed
but the patient died at 22 months after initial diagnosis. magnification 400T) (b) of primary tumour (1a-b), first (2a-b)
g of the primary meningioma (MG) with surrounding
, two mitoses (red arrows). (For interpretation of the
 the web version of this article.)
Fig. 3 – (a) Parasagittal spread of MG (yellow arrows). (b) Anaplastic MG. Clear-cut features of cellular atypia, two mitoses, one
of them atypical (red arrows). (For interpretation of the references to color in this figure legend, the reader is referred to the
web version of this article.)
Fig. 2 – (a) 6-months postoperative CT; the relapsed MG (black arrows). (b) Features of atypia including enlarged nuclei and
prominent nucleoli, three mitoses (red arrows). (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
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3.1. Genetic evaluation
Tumour samples were collected intraoperatively for the
histopathological and molecular analysis. The genomic DNA
was isolated from the tumour tissues (stored in 80 8C) and
peripheral blood leukocytes. Using the chloroform phenol
method, the quantiﬁcation and the analysis with respect to
purity and protein content was performed and the markers were
selected from NCBI database (ncbi.nlm.nih.gov). Paired DNA
samples were analysed for loss of heterozygosity (LOH) with
24 microsatellite markers (HVD Holding AG; Ebersberg,Germany). The following microsatellite loci were tested:
D1S508, D1S199, D1S197, D1S162, D9S156, D9S162, D9S319,
D9S1748, D10S197, D10S209, D10S587, D10S1709, D14S292,
D14S1010, D22S257, D22S258, D22S268, D22S298, D22S303,
D22S449, D22S609, D22S1150, and D22S1163. The polymerase
chain reaction (PCR) was performed according to a standard
protocol. The products were electrophoresed on 6% denaturing
polyacrylamide gel (containing 7 mol/L urea); for visualisation
LiCor automatic sequencer (LiCor Biotechnology, Lincoln, NE,
USA) was used. A reduction intensity of >50% in the tumour lane
compared to the corresponding blood lane was regarded as LOH
and was repeatedly analysed. Histopathological examination:
4% solution of buffered formaldehyde; dehydrated after 10–24 h
of ﬁxation; cleared and impregnated with parafﬁn in tissue
Table 1 – Genetic profile of the tumour: initial (0), during first relapse (I) and second relapse (II). Loss of heterozygosity at
chromosome 1 was marked with an exclamation mark (!) to emphasise that molecular progression to anaplastic
meningioma actually proceeded histopathological progression.
LOH at chromosome 1 9 10 14 22 Histopathology
0   + + + Atypical
Recurrence I8 + (!)  + + + Atypical
II8 +  + + + Anaplastic
Abbreviation: LOH, loss of heterozygosity.
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were prepared; stained by haematoxylin and eosin. Immunos-
tains with progesterone receptor antibodies, epithelial mem-
brane antigen (EMA) and MIB-1 were obtained. The tumour was
classiﬁed according to the WHO criteria [4,10].
4. Results
The loss of heterozygosity (LOH) at chromosomes 10, 14 and 22
was conﬁrmed in the primary tumour sample. An additional
aberration occurred, LOH at chromosome 1 even though the
histopathology was atypical. The genetic proﬁle of the tumour
during the second surgery has not changed, but the tumour
progressed histologically (Table 1).
5. Discussion
At least 20% of MGs recur. The relapsed tumours pose a clinical
challenge as they are more difﬁcult to remove safely. However,
atypical (Grade 2) MGs recur 8 times more often than Grade 1
MGs. Atypical MGs not only tend to recur but also dedifferen-
tiate to the more malignant, anaplastic (Grade 3) MG.
According to WHO classiﬁcation Grade 2 MGs are deﬁned by
one or more of the following four criteria: (1) chordoid or clear
cell histologic subtype, (2) 4–19 mitoses per ten high-power
ﬁeld (HPF), (3) brain inﬁltration, and (4) three or more of the
following ﬁve histologic features: small cell change, increased
cellularity, prominent nucleoli, sheet-like growth, or necrosis.
Grade 3 (anaplastic/malignant) MGs are deﬁned by rhabdoid or
papillary subtypes, a histological picture of frank malignancy
resembling that of carcinomas, melanomas, or high grade
sarcomas, or 20 or more mitosis per ten high-power ﬁeld (HPF).
The risk of death in 2 years from diagnosis is greatly increased
if a malignant tumour is diagnosed [2,11,12]. The sentence is
not clear for me. Tumours that fulﬁl the strict WHO criteria of
atypical meningioma can clinically behave either as a benign
Grade 1 tumour or malignant tumour Grade 3 in WHO scale
[13]. This can be explained in terms of molecular alterations,
which supplement the histopathological and immunohisto-
chemical diagnosis. On the contrary, the cytogenetic studies
indicated areas of various molecular patterns in a single lesion
[14]. The existence of these heterogeneous regions in the MG
can partially explain LOH at chromosome 1, which overtook
the histological progression to the anaplastic form. The
evolutional mechanism resembles glioma behaviour; some
are de novo tumours while some are secondary. In fact,
these two forms of gliomas differ in genetic proﬁle and require
different treatment [15]. Unfortunately, MGs have not beenwidely studied in terms of de novo and secondary occurrence.
Based on the results of comparative genomic hybridisation
method and gene expression investigations, the diagnosis of
either low- or highly proliferative MG relies on the molecular
signature, regardless of the tumour's histopathological type
[2,16]. Patients with atypical MGs can beneﬁt the most from
the molecular evaluation. Riemenschneider et al. summarised
the cytogenetic changes associated with the progression of
atypical MG [17]. It was attributed to LOH at chromosomes 6, 9,
10, 14 and 17. On the other hand, 1p losses were found in up to
26% of Grade 1, <76% of Grade 2 and in almost every anaplastic
MG [8]. Moreover, LOH on 1p was associated with malignant
progression of the recurrent MG, even if no speciﬁc gene was
found [8,18,19].
In the presented a case, the initial diagnosis was Grade 2
MG with a typical clinical and radiological picture. The
molecular ﬁndings were also typical for Grade 2 tumour,
including LOH at chromosome 14. That alteration lead to the
loss of suppressor genes such as MEG3 and NDRG2 [20,21]. The
another initially diagnosed aberration was LOH at chromo-
some 10, which correlate with shorter survival time and higher
recurrence rate [22]. On the contrary, the cytogenetic role of the
chromosome 22 anomaly is not linked with aggressive
behaviour [23]. The investigations of BCR, TIMP3, and ELAVL4
did not conﬁrm their role in MG progression [24–27].
The examination of the recurred tumour revealed LOH on 1p,
although without histopathological progression. The anaplasia
was found until the second relapse was recognised. The delay of
anaplastic transformation was evident. Furthermore, in the
presented case the LOH at chromosome 1 was probably required
to complement other alterations. The complex mutations
together with their sequence underlies the progression mecha-
nism [28]. Al-Mefty et al. found complex genetic aberrations in
3 of 4 MG samples prior to anaplastic transformation. He
suggested that a certain subpopulation of benign MGs are
'programmed' to progress to the anaplastic form [29]. Krayen-
buhl et al. compared cytogenetic proﬁle of de novo and
secondary MGs (that progressed from atypical) [30]. In his study,
the alterations on chromosomes 1, 10, 14, 18 and 22 were more
frequent in progressed MGs than in the de novo form. Moreover,
9pdeletion as well as ampliﬁcation of 17p23 are characteristic for
anaplastic MG [8], though not present in our case nor examined
routinely. The question whether the above alterations charac-
terise only de novo MGs remains still unanswered.
6. Conclusions
Anaplastic MGs can progress from the atypical form. The
molecular progression can precede histopathological progres-
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the original tumours and of the recurrences in the same
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